Publications by authors named "Joy Olbertz"

Claim this Profile
C
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.
Marianna Fontana, Scott D Solomon, Jessica Kachadourian, Liron Walsh, Ricardo Rocha, Joy Olbertz

N Engl J Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
Madhukar Aryal, Kelly Lau, Ryan Boyer, Huiyu Zhou, Johanna Abend, Joy Olbertz

Mol Genet Metab· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.
Yulan Qi, Gina Patel, Joshua Henshaw, Soumi Gupta, Joy Olbertz

Clin Transl Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
Geoffrey Y Berguig, Nathan T Martin, Athena Y Creer, Lin Xie, Lening Zhang, Joy Olbertz

Mol Genet Metab· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.
Soumi Gupta, Kelly Lau, Cary O Harding, Gillian Shepherd, Ryan Boyer, Joy Olbertz

EBioMedicine· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
Janet Thomas, Harvey Levy, Stephen Amato, Jerry Vockley, Roberto Zori, Joy Olbertz

Mol Genet Metab· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
Robert M Lester, Joy Olbertz

Expert Rev Clin Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding.
Keith A Moore, Timothy S Callahan, Pierre Maison-Blanche, Isabelle Morin, Ted Marenco, Joy Olbertz

Expert Opin Pharmacother· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptotic resistance exhibited by dexamethasone-resistant murine 7TD1 cells is controlled independently of interleukin-6 triggered signaling.
Kalyan J Gangavarapu, Joy L Olbertz, Alok Bhushan, James C K Lai, Christopher K Daniels

Apoptosis· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis